|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400085954 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-17 09:55:02 |
|
注册时间: Date of Registration: |
2024-06-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
冠心病合并糖尿病中医诊疗方案循证优化研究 |
|
Public title: |
Study on evidence-based optimization of TCM diagnosis and treatment scheme for coronary heart disease complicated with diabetes |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
冠心病合并糖尿病中医诊疗方案循证优化研究 |
|
Scientific title: |
Study on evidence-based optimization of TCM diagnosis and treatment scheme for coronary heart disease complicated with diabetes |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李京 |
研究负责人: |
刘宁 |
|
Applicant: |
LI Jing |
Study leader: |
LIU Ning |
|
申请注册联系人电话: Applicant telephone: |
+86 135 1426 7886 |
研究负责人电话:
Study leader's |
+86 188 4052 9158 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lijing86826@163.com |
研究负责人电子邮件: Study leader's E-mail: |
410845168@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
研究负责人通讯地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
|
Applicant address: |
No. 33 Beiling Street, Huanggu District, Shenyang City, Liaoning Province |
Study leader's address: |
No. 33 Beiling Street, Huanggu District, Shenyang City, Liaoning Province |
|
申请注册联系人邮政编码: Applicant postcode: |
110033 |
研究负责人邮政编码: Study leader's postcode: |
110033 |
|
申请人所在单位: |
辽宁中医药大学附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
辽宁中医药大学附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024031CS(KT)-010-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
辽宁中医药大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-23 00:00:00 | ||
|
伦理委员会联系人: |
李晓 |
||
|
Contact Name of the ethic committee: |
LI Xiao |
||
|
伦理委员会联系地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
||
|
Contact Address of the ethic committee: |
No. 33 Beiling Street, Huanggu District, Shenyang City, Liaoning Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 181 0245 9168 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
辽宁中医药大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
辽宁省沈阳市皇姑区北陵大街33号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 33 Beiling Street, Huanggu District, Shenyang City, Liaoning Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
辽宁省科技计划联合计划应用基础研究项目2023JH2/101700229 |
||||||||||||||||||||||
|
Source(s) of funding: |
Liaoning Province Science and Technology Plan Joint Program Application Basic Research Project 2023JH2/101700229 |
||||||||||||||||||||||
|
研究疾病: |
冠心病合并糖尿病 |
||||||||||||||||||||||
|
Target disease: |
Coronary heart disease complicated with diabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
明确辽宁地区冠心病合并糖尿病病案的临床表现、证候特点、治则治法、代表性方药、辨证施护、健教康养信息。 |
||||||||||||||||||||||
|
Objectives of Study: |
To clarify the clinical manifestations, syndrome characteristics, treatment principles and methods, representative prescriptions and drugs, syndrome differentiation nursing, health education and health care information of coronary heart disease complicated with diabetes in Liaoning. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.同时符合冠心病及糖尿病中、西医诊断标准的患者; 2.年龄在 30-89 岁之间的患者; 3.中西医诊治信息规范全面的病历数据。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients who meet the diagnostic criteria of both Chinese and Western medicine for coronary heart disease and diabetes; 2. Patients aged between 30 and 89 years old; 3. Standardized and comprehensive medical record data for diagnosis and treatment of traditional Chinese and Western medicine |
||||||||||||||||||||||
|
排除标准: |
1.合并严重的瓣膜性心脏病(如风湿性心脏病)、各种类型心肌病(如扩张性心肌病、肥厚性心肌病)、恶性心律失常(如永久性、持续性房颤,Ⅲ度房室传导阻滞等)、感染性心内膜炎、先天性心脏病等冠状动脉疾病以外的严重心脏病患者; 2.糖尿病急性并发症的患者(如高渗性昏迷,糖尿病酮症酸中毒及糖尿病急性感染)、糖尿病认知功能障碍的患者、I 型糖尿病患者、特殊类型糖尿病患者; 3.未经控制的高血压(Bp≥180/110mmHg)患者; 4.PaO2<60mmHg 的严重肺功能不全患者、转氨酶水平超过正常值上限的 3 倍的中重度肝功能不全、eGFR<30ml/min/1.73m2 的中重度肾功能不全的患者; 5.内分泌和造血系统有严重的原发性疾病、近 3 个月新患急性脑血管疾病或已诊断严重风湿免疫系统疾病者的患者; 6.精神病患者; 7.怀孕或哺乳期者; 8.预期寿命<1 年; 9.住院天数小于 3 天的患者; 10.证侯与临床表现不符的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with severe valvular heart disease (such as rheumatic heart disease), various types of cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy), malignant arrhythmias (such as permanent and persistent atrial fibrillation, third degree atrioventricular block, etc.), infectious endocarditis, congenital heart disease, and other serious heart disease other than coronary artery diseases; 2. Patients with acute complications of diabetes (such as hypertonic coma, diabetes ketoacidosis and diabetes acute infection), patients with diabetes-related cognitive dysfunction, patients with type I diabetes, and patients with special types of diabetes; 3. Patients with uncontrolled hypertension (Bp ≥ 180/110mmHg); 4. Patients with severe pulmonary insufficiency with PaO2<60mmHg, patients with moderate and severe hepatic insufficiency with transaminase level exceeding 3 times the upper limit of normal value, and patients with moderate and severe renal insufficiency with eGFR < 30ml/min/1.73m2; 5. Patients with severe primary diseases in the endocrine and hematopoietic systems, newly diagnosed acute cerebrovascular diseases in the past three months, or diagnosed with severe rheumatic and immune system diseases; 6. Patients with mental illness; 7. Pregnant or lactating individuals; 8. Life expectancy<1 year; 9. Patients who have been hospitalized for less than 3 days; 10. Patients whose symptoms do not match clinical manifestations. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-12-01 00:00:00至 To 2025-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-06-30 00:00:00 至 To 2025-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Medical record form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |